DAY 2 - Monday, May 7
RETINA
IVAN, CATT studies assess efficacy of two AMD drugs
Fort Lauderdale, FL—The 2-year results of the Comparison of AMD Treatment Trials (CATT) indicate that bevacizumab (Avastin, Genentech) is equivalent to ranibizumab (Lucentis, Genentech) for treating wet age-related macular degeneration (AMD) when similar dosing regimens are compared. In addition, the 1-year results of the randomized controlled trial of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN) were presented during a special session at the ARVO annual meeting. » MORE
Neuropeptide could have role in retinal trauma
Fort Lauderdale, FL—In studies that could have bearing on the treatment of soldiers and others who experience trauma to the retina or central nervous system, Joan Stein-Streilein, PhD, has hypothesized that the receptor antagonist of Substance P, a neuroinflammatory peptide, may have a therapeutic role. » MORE
Visual acuity advances seen with Leber’s congenital amaurosis
Fort Lauderdale, FL—Five gene therapy trials are under way in Leber’s congenital amaurosis (LCA)—three in the United States, one in the United Kingdom, and one in Israel. William W. Hauswirth, PhD, reviewed the advances in gene therapy treatment of LCA. » MORE
KEYNOTE SESSION
More innovations likely from genomics expert Venter
Fort Lauderdale, FL—J. Craig Venter, PhD, founder, chairman, and president of the J. Craig Venter Institute, is perhaps most famous for his contributions to genomic research, including the sequencing of the first human genome, published in 2001. However, the scientist-entrepreneur and his teams continue to investigate new ideas that are likely to affect health, medicine, food, energy use, and untold other aspects of daily life. Dr. Venter was the featured speaker during the ARVO/Alcon keynote session Sunday evening. » MORE
CORNEA
Biomaterials regenerate corneal tissues, nerves
Fort Lauderdale, FL—Biometric polymers can be used to tissue engineer biointeractive scaffolds for regeneration of human corneas. Results after 4 years in a phase I study of 10 patients with keratoconus or deep central scarring show stable integration of artificial corneas made from a combination of collagen and other components, said May Griffith, PhD, MBA. » MORE
GLAUCOMA
New structure-function index evaluates glaucoma progression
Fort Lauderdale, FL—A combined index of structure and function in glaucoma is critical as a means of establishing a clinical endpoint that can demonstrate the effectiveness of therapeutic intervention in studies of neuroprotection, said Robert Weinreb, MD. » MORE
Genetic modification of trabecular meshwork explored
Fort Lauderdale, FL—Gene transfer therapy is being studied to explore the pathophysiology of glaucomatous increases in IOP and identify new target genes and delivery mechanisms for treating glaucoma in the future, said Abbot Clark, PhD. » MORE
Mesenchymal stem cells have strong neuroprotective effect
Fort Lauderdale, FL—Mesenchymal stem cells seem to have a strong neuroprotective effect in glaucoma, said Keith R. Martin, PhD, who described the work in his laboratory. » MORE
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
